Forecast

There is no analyst data available for this company.

News Go to news feed

Acumen Pharmaceuticals unveils new Alzheimer strategy with sabirnetug at Citi conference

Acumen Pharmaceuticals presented its approach to treating Alzheimer’s at Citi’s “Biopharma Back to School Conference,” focusing on the antibody sabirnetug against Aβ oligomers, plans for a subcutaneous formulation, and improved brain targeting in collaboration with JCR Pharmaceuticals. The company emphasized use of biomarkers (including pTau217), AI/ML analyses for data processing, reported positive Phase 1 signals, and highlighted the ongoing ALTITUDE‑AD study for further validation. Acumen sees combination therapies as the future and expects a preclinical EBD candidate in early 2026. » More on de.investing.com
Acumen Pharmaceuticals misses Q2 forecast and shares slip in premarket

Acumen Pharmaceuticals reported Q2 2025 EPS of -$0.68, missing the estimate of -$0.51, which led to a 1.41% decline in premarket trading. Higher R&D expenses drove the net loss to $41 million; cash and cash equivalents stood at $166.2 million and are expected to last into early 2027. The company reaffirmed its collaboration with JCR Pharmaceuticals and expects top-line data from the Phase 2 ALPITUDE AD study by the end of 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, JCR PHARM. has already paid €0.0544 in dividends. The last payout was in June.

Financials

In the last quarter, JCR PHARM. had revenue of €52.26M and net profit of -€10.28M

(EUR)	June 2026	YoY
Revenue	52.26M	3.37%
Gross profit	40.14M	10.20%
Net profit	-10.28M	219.11%
EBITDA	-8.54M	2,294.36%

Fundamentals

Metric	Value
Market capitalization	€362.58M
Number of shares	122.02M
52-week high/low	€4.62 - €2.49
Dividend yield	3.80%
Dividends TTM	€0.11
Beta	0.42
P/E ratio	78.87
PEG ratio	1.21
P/B ratio	1.50
P/S ratio	1.56

Company profile

JCR Pharmaceuticals Co. Ltd. ist ein Spezialpharmaunternehmen, das sich mit der Erforschung, Entwicklung, Herstellung, dem Import und Export sowie dem Verkauf von pharmazeutischen Produkten, regenerativen Arzneimitteln und Drogensubstanzen in Japan beschäftigt. Es bietet verschiedene therapeutische Produkte an, darunter GROWJECT zur Behandlung von Wachstumshormonmangel und Kleinwuchs, IZCARGO zur Behandlung von Mukopolysaccharidose Typ II, Agalsidase Beta BS I.V. Infusion zur Behandlung der Fabry-Krankheit und TEMCELL HS Inj zur Behandlung der akuten Graft-versus-Host-Krankheit. Das Unternehmen entwickelt auch Epoetin Alfa BS und Darbepoetin Alfa BS Injektionen für die Behandlung von renaler Anämie. Darüber hinaus vertreibt das Unternehmen medizinische Geräte und Laborinstrumente. JCR Pharmaceuticals Co., Ltd. wurde 1975 gegründet und hat seinen Hauptsitz in Ashiya, Japan.